Eli Lilly and Co. (LLY) Position Boosted by Savant Capital LLC
Savant Capital LLC raised its stake in Eli Lilly and Co. (NYSE:LLY) by 1.4% during the second quarter, Holdings Channel reports. The firm owned 7,189 shares of the company’s stock after buying an additional 100 shares during the period. Savant Capital LLC’s holdings in Eli Lilly and were worth $566,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its position in Eli Lilly and by 565.1% in the first quarter. Renaissance Technologies LLC now owns 2,213,605 shares of the company’s stock valued at $159,402,000 after buying an additional 1,880,800 shares during the period. Beutel Goodman & Co Ltd. acquired a new position in Eli Lilly and during the second quarter valued at approximately $104,345,000. Bank of Montreal Can acquired a new position in Eli Lilly and during the second quarter valued at approximately $86,545,000. Franklin Resources Inc. boosted its position in Eli Lilly and by 3.6% in the first quarter. Franklin Resources Inc. now owns 27,744,978 shares of the company’s stock valued at $1,997,920,000 after buying an additional 961,204 shares during the period. Finally, NN Investment Partners Holdings N.V. acquired a new position in Eli Lilly and during the first quarter valued at approximately $61,280,000. Institutional investors and hedge funds own 74.96% of the company’s stock.
Shares of Eli Lilly and Co. (NYSE:LLY) traded up 0.76% during midday trading on Friday, hitting $82.09. The stock had a trading volume of 4,241,408 shares. Eli Lilly and Co. has a 52 week low of $67.88 and a 52 week high of $88.16. The stock has a 50-day moving average of $79.37 and a 200 day moving average of $77.41. The stock has a market cap of $86.83 billion, a PE ratio of 35.38 and a beta of 0.17.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 26th. The company reported $0.86 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.86. Eli Lilly and had a net margin of 11.97% and a return on equity of 23.99%. The firm earned $5.40 billion during the quarter, compared to analyst estimates of $5.14 billion. During the same quarter in the prior year, the business posted $0.90 earnings per share. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. Analysts anticipate that Eli Lilly and Co. will post $3.59 EPS for the current fiscal year.
Several research analysts recently commented on LLY shares. Jefferies Group boosted their price target on Eli Lilly and from $100.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, July 14th. Goldman Sachs Group Inc. raised Eli Lilly and from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $89.00 to $95.00 in a report on Tuesday, September 27th. Zacks Investment Research lowered Eli Lilly and from a “buy” rating to a “hold” rating in a report on Thursday, August 4th. Argus boosted their price objective on Eli Lilly and from $90.00 to $95.00 and gave the company a “buy” rating in a report on Tuesday, August 2nd. Finally, JPMorgan Chase & Co. raised Eli Lilly and from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $92.00 to $95.00 in a report on Thursday, September 8th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $97.16.
In other news, insider Maria A. Crowe sold 2,248 shares of the firm’s stock in a transaction that occurred on Wednesday, October 5th. The shares were sold at an average price of $81.37, for a total transaction of $182,919.76. Following the completion of the sale, the insider now owns 94,319 shares of the company’s stock, valued at $7,674,737.03. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 12th. The stock was sold at an average price of $79.54, for a total transaction of $16,703,400.00. Following the sale, the insider now directly owns 126,220,804 shares of the company’s stock, valued at approximately $10,039,602,750.16. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by corporate insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co. (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.